EXAS vs. THC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EXAS and THC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | EXAS | THC |
|---|---|---|
| Company Name | Exact Sciences Corporation | Tenet Healthcare Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Providers & Services |
| Market Capitalization | 12.87 billion USD | 17.15 billion USD |
| Exchange | NasdaqCM | NYSE |
| Listing Date | February 1, 2001 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of EXAS and THC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EXAS | THC |
|---|---|---|
| 5-Day Price Return | 0.68% | -0.91% |
| 13-Week Price Return | 47.00% | 12.14% |
| 26-Week Price Return | 24.89% | 22.33% |
| 52-Week Price Return | 32.13% | 18.40% |
| Month-to-Date Return | 3.62% | -6.58% |
| Year-to-Date Return | 19.29% | 52.82% |
| 10-Day Avg. Volume | 3.67M | 0.89M |
| 3-Month Avg. Volume | 2.86M | 1.20M |
| 3-Month Volatility | 29.23% | 31.48% |
| Beta | 1.43 | 1.43 |
Profitability
Return on Equity (TTM)
EXAS
-40.39%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
EXAS has a negative Return on Equity of -40.39%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
THC
33.61%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
THC’s Return on Equity of 33.61% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
EXAS
-32.01%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
EXAS has a negative Net Profit Margin of -32.01%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
THC
6.49%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
A Net Profit Margin of 6.49% places THC in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
EXAS
-32.45%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
EXAS has a negative Operating Profit Margin of -32.45%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
THC
16.67%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
An Operating Profit Margin of 16.67% places THC in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | EXAS | THC |
|---|---|---|
| Return on Equity (TTM) | -40.39% | 33.61% |
| Return on Assets (TTM) | -16.91% | 4.66% |
| Net Profit Margin (TTM) | -32.01% | 6.49% |
| Operating Profit Margin (TTM) | -32.45% | 16.67% |
| Gross Profit Margin (TTM) | 67.37% | 82.26% |
Financial Strength
Current Ratio (MRQ)
EXAS
2.72
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
EXAS’s Current Ratio of 2.72 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
THC
1.71
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
THC’s Current Ratio of 1.71 is in the upper quartile for the Health Care Providers & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
EXAS
0.94
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
EXAS’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 0.94. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
THC
3.29
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
With a Debt-to-Equity Ratio of 3.29, THC operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
EXAS
-15.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
EXAS has a negative Interest Coverage Ratio of -15.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
THC
10.27
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
THC’s Interest Coverage Ratio of 10.27 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | EXAS | THC |
|---|---|---|
| Current Ratio (MRQ) | 2.72 | 1.71 |
| Quick Ratio (MRQ) | 2.24 | 1.56 |
| Debt-to-Equity Ratio (MRQ) | 0.94 | 3.29 |
| Interest Coverage Ratio (TTM) | -15.18 | 10.27 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
THC
0.00%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
THC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
THC
0.00%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
THC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | EXAS | THC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
EXAS
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for EXAS is currently unavailable.
THC
12.61
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
In the lower quartile for the Health Care Providers & Services industry, THC’s P/E Ratio of 12.61 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
EXAS
4.12
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
In the lower quartile for the Biotechnology industry, EXAS’s P/S Ratio of 4.12 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
THC
0.82
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
THC’s P/S Ratio of 0.82 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
EXAS
4.14
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
EXAS’s P/B Ratio of 4.14 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
THC
4.47
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
THC’s P/B Ratio of 4.47 is in the upper tier for the Health Care Providers & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | EXAS | THC |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 12.61 |
| Price-to-Sales Ratio (TTM) | 4.12 | 0.82 |
| Price-to-Book Ratio (MRQ) | 4.14 | 4.47 |
| Price-to-Free Cash Flow Ratio (TTM) | 51.33 | 7.89 |